Intellectual Property,
Health Care & Hospital Law
Mar. 30, 2021
Companies say patent action could hamper vaccine work
“This court should dismiss Allele’s amended complaint ... before this lawsuit becomes another burden on Pfizer and BioNTech as they continue their work on this vital vaccine,” wrote David J. Noonan of Noonan Lancer Boyer & Banach and Elizabeth Braun of Paul Hastings LLP.
Pfizer and BioNTech filed a second motion to dismiss a patent action pursued by Allele Biotechnology, warning that the case could become "a burden" on COVID-19 vaccine development efforts.
Allele sued Pfizer and BioNTech in October, maintaining that the companies, without permission, used its mNeonGreen fluorescent protein as a research tool during the vaccine's clinical trial stage. Allele was granted a patent on its mNeonGreen on ...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In